Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02498405
Other study ID # 1040562
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 2015

Study information

Verified date July 2018
Source Intermountain Health Care, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary objective of this study is to determine if the Smartphone electrocardiogram (ECG) is an acceptable replacement for a standard ECG in the identification of ST Elevation Myocardial Infarction (STEMI).

Toward this objective, this study involves the following:

- Obtain simultaneous recordings of a standard 12-lead ECG and the iPhone "12-lead equivalent" ECG on patients presenting with chest pain in which the STEMI protocol was activated.

- Obtain simultaneous recordings of a standard 12-lead ECG and the iPhone "12-lead equivalent" ECG on patients presenting to the Emergency Department for evaluation of chest pain, not necessarily presenting with STEMI.

- Reading of ECGs (standard 12-lead and iPhone) by three independent cardiologists, who are blinded to the initial clinical ECG readings, the type of ECG equipment used, and the patient's clinical information.

- Assess the operational feasibility of using the Smartphone to obtain "12-lead equivalent" ECG recordings in patients suspected to have STEMI, and

- Determine the possibility of pooling the data obtained from this study with data from other institutions conducting identical studies, and developing a future IRB-approved protocol and statistical analysis plan to compare the sensitivity, specificity, positive predictive value and the negative predictive power of the iPhone ECG, using a paired standard 12-lead ECG as the gold standard.

There will be no therapeutic interventions. A single research-related procedure will be required, i.e. an iPhone ECG. Effort will be made to ensure that the performance of this procedure will not delay any treatment and/or diagnostic procedures that are part of usual or specialized care that the patient requires. Effort will be made to enroll 1 STEMI patient for every 2 non-STEMI patients.


Recruitment information / eligibility

Status Completed
Enrollment 53
Est. completion date
Est. primary completion date October 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female >= 18 years of age.

- Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures (patient or legally acceptable representative).

- Symptoms of chest pain upon presentation at the Intermountain Medical Center Emergency Department.

Exclusion Criteria:

- Inability or refusal of the patient and/or the patient's legally-acceptable representative to provide written informed consent for any reason.

- Other conditions that in the opinion of the Principal Investigator or Co-Investigator(s) may increase risk to the subject and/or compromise the quality of the clinical trial.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Intermountain Medical Center Murray Utah

Sponsors (1)

Lead Sponsor Collaborator
Intermountain Health Care, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnosis differences Determine the number of agreements in diagnoses (STEMI vs. non-STEMI) between the standard 12-lead ECG and the iPhone "12-lead equivalent" ECG. 1 day
See also
  Status Clinical Trial Phase
Recruiting NCT02869906 - Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment of Non Culprit Lesions in Patients With ST-segment Elevation Myocardial Infarction N/A
Not yet recruiting NCT03895983 - ST Segment Resolution After Primary Percutaneous Coronary Intervention.
Not yet recruiting NCT03252665 - Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients Undergoing Primary PCI Phase 4
Completed NCT02026219 - Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction Phase 4
Completed NCT03247738 - Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI Phase 4
Recruiting NCT05461781 - Distal Transradial Access for Primary PCI in STEMI Patients to Prevent RAO N/A
Recruiting NCT03561389 - iFR-guided Revascularization in STEMI
Completed NCT01538303 - Microvascular Dysfunction in Acute Myocardial Infarction (AMI) and Its Relation to Outcome
Recruiting NCT02979236 - Italian Multi-center Registry of Self-apposing Coronary Stent in Patients With STEMI N/A
Completed NCT05705089 - Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI Phase 3
Completed NCT01897350 - Myocardial Oedema in ST Segment Elevation Myocardial Infarction Myocardial N/A
Not yet recruiting NCT03753269 - Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction Phase 4
Completed NCT03234348 - MAGnesium-based Bioresorbable Scaffold in ST Segment Elevation Myocardial Infarction Phase 3
Recruiting NCT03406832 - Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI N/A
Recruiting NCT03406819 - Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI N/A
Recruiting NCT03508232 - Doxycycline to Protect Heart Muscle After Heart Attacks Phase 2
Recruiting NCT04220736 - Early Prediction of QFR in STEMI-Pharmaco-invasice
Completed NCT03780335 - Early Prediction of QFR in STEMI-I
Recruiting NCT03787745 - Ischemic Postconditioning in STEMI Patients Treated With Primary PCI N/A
Recruiting NCT03621111 - A Trial on the Role of Community Pharmacist in Improving Adherence and Clinical Outcomes in Post-Infarction N/A